enVVeno Medical Corporation (NASDAQ:NVNO – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 18,286 shares, an increase of 68.7% from the July 15th total of 10,839 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average trading volume of 19,970 shares, the short-interest ratio is presently 0.9 days.
enVVeno Medical Stock Down 6.5%
Shares of enVVeno Medical stock opened at $11.03 on Wednesday. enVVeno Medical has a 52-week low of $8.67 and a 52-week high of $177.39. The company’s 50-day simple moving average is $10.70 and its 200-day simple moving average is $10.73. The firm has a market cap of $7.50 million, a price-to-earnings ratio of -0.57 and a beta of 1.09.
enVVeno Medical (NASDAQ:NVNO – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($5.37) EPS for the quarter, missing analysts’ consensus estimates of ($4.69) by ($0.68). Equities research analysts anticipate that enVVeno Medical will post -16.19 EPS for the current year.
Wall Street Analyst Weigh In
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in enVVeno Medical in the second quarter worth $51,000. Creative Planning acquired a new position in shares of enVVeno Medical during the 2nd quarter worth $54,000. ACT Capital Management LLC acquired a new position in shares of enVVeno Medical during the 4th quarter worth $37,000. Geode Capital Management LLC increased its holdings in shares of enVVeno Medical by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock valued at $796,000 after purchasing an additional 2,211 shares in the last quarter. Finally, CM Management LLC increased its holdings in shares of enVVeno Medical by 108.3% in the 4th quarter. CM Management LLC now owns 1,250,000 shares of the company’s stock valued at $401,000 after purchasing an additional 650,000 shares in the last quarter. Institutional investors and hedge funds own 34.71% of the company’s stock.
enVVeno Medical Company Profile
enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.
The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.
Featured Stories
- Five stocks we like better than enVVeno Medical
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
